ALXN.O
Latest Trade
106.32USDChange
0.65(+0.62%)Volume
2,598,280Today's Range
-
106.9652 Week Range
-
141.86As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 105.67 |
|---|---|
Open | 105.15 |
Volume | 2,598,280 |
3M AVG Volume | 50.36 |
Today's High | 106.96 |
Today's Low | 104.07 |
52 Week High | 141.86 |
52 Week Low | 92.56 |
Shares Out (MIL) | 224.23 |
Market Cap (MIL) | 23,694.05 |
Forward P/E | 10.65 |
Dividend (Yield %) | -- |
Alexion And Bridgebio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis Investigational Medicine
Alexion Pharmaceuticals Says European Patent Office To Not Grant Co Patent Application Relating To Pharmaceutical Composition Of Soliris
Alexion Pharmaceuticals Q2 Non-GAAP Earnings Per Share $2.64
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
Industry
Major Drugs
Executive Leadership
David R. Brennan
Independent Chairman of the Board
Ludwig N. Hantson
Chief Executive Officer, Director
Paul J. Clancy
Chief Financial Officer, Executive Vice President
Indrani Franchini
Executive Vice President, Chief Compliance Officer
Ellen Chiniara
Executive Vice President, General Counsel, Corporate Secretary
Price To Earnings (TTM) | 19.24 |
|---|---|
Price To Sales (TTM) | 5.27 |
Price To Book (MRQ) | 2.33 |
Price To Cash Flow (TTM) | 14.49 |
Total Debt To Equity (MRQ) | 26.03 |
LT Debt To Equity (MRQ) | 24.73 |
Return on Investment (TTM) | 9.53 |
Return on Equity (TTM) | 8.83 |
The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday.
The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.
Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.
Alexion Pharmaceuticals Inc, the maker of an expensive blood disorder treatment, has agreed to pay $13 million to resolve a U.S. Department of Justice probe into its financial support of charities that help Medicare patients cover out-of-pocket drug costs.
The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.
The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc's blood disorder drug Ultomiris, the pharma regulator's website showed https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108 on Friday.
Alexion Pharmaceuticals Inc <ALXN.O> said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.
Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, giving it access to a rare blood disorder drug.
* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY
* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRIS® (ECULIZUMAB)
The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:
Alexion Pharmaceuticals <ALXN.O> has agreed to buy Sweden's Wilson Therapeutics <WTX.ST> for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.
Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million) to boost its line-up of rare disease drugs.
* SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER
* ALEXION PHARMACEUTICALS SAYS CEO LUDWIG HANTSON'S TOTAL FY 2017 COMPENSATION WAS $15.3 MILLION - SEC FILING
Alexion Pharmaceuticals Inc said its experimental drug to treat a rare blood disorder showed in an eagerly awaited study that it was not inferior to its flagship drug, Soliris, paving the way for the company to establish a dominant position in the market as competition looms...
* ALEXION ANNOUNCES POSITIVE TOP-LINE RESULTS SHOWING SUCCESSFUL PHASE 3 CLINICAL STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Alexion Pharmaceuticals Inc said its experimental drug, ALXN1210, met the main goal in a late-stage study in patients with a rare blood disorder.
* ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES FINANCIAL GUIDANCE FOR 2018
Alexion Pharmaceuticals Inc said on Tuesday it had agreed to work with hedge fund Elliott Management to identify a new member to join the drugmaker's board.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.